Recent advances in the pathology of cutaneous drug eruptions (Q33690067)

28 July 2017

1 reference

title

Recent advances in the pathology of cutaneous drug eruptions (English)

1 reference

28 July 2017

Crowson AN

1

1 reference

28 July 2017

Magro CM

series ordinal

2

1 reference

28 July 2017

publication date

1 July 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

17

1 reference

28 July 2017

issue

3

1 reference

28 July 2017

page(s)

537-60, viii

1 reference

Nonpigmented fixed drug eruption from pseudoephedrine

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Role of delayed cellular hypersensitivity and adhesion molecules in amoxicillin-induced morbilliform rashes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Clinically significant drug interactions in dermatology

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Drugs associated with bullous pemphigoid. A case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Recognition of pemphigus antigens in drug-induced pemphigus vulgaris and pemphigus foliaceus

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Fixed drug eruption to three anticonvulsant drugs: an unusual case of polysensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Iododerma after computed tomographic scan with intravenous radiopaque contrast media

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Terbinafine-induced acute generalized exanthematous pustulosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Diltiazem and subacute cutaneous lupus erythematosus-like lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Lichenoid and subacute cutaneous lupus erythematosus-like dermatitis associated with antihistamine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Cutaneous reactions to recombinant human interferon beta-1b: the clinical and histologic spectrum

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Drug-induced linear IgA bullous dermatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

A generalized cutaneous reaction induced by granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Nonpigmenting solitary fixed drug eruption caused by pseudoephedrine hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Cutaneous nodular reaction to oral mercury

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Carbamazepine-induced thrombocytopenia and leucopenia complicated by Henoch-Schönlein purpura symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Drug induced acute generalized exanthematous pustulosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Purpuric drug eruption secondary to itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

A comparative study of adverse drug reactions reported through hospital and private medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Contribution of perforin-positive cell infiltration

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Adverse cutaneous reactions to psychotropic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

The clinical and histomorphological features of pityriasis rubra pilaris. A comparative analysis with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Drug-induced immune dysregulation as a cause of atypical cutaneous lymphoid infiltrates: a hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Drugs with antihistaminic properties as a cause of atypical cutaneous lymphoid hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Pseudoporphyria associated with Relafen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Drugs causing fixed eruptions: a study of 450 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

A prospective study of adverse drug reactions as a cause of admission to a paediatric hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Drug-induced acute generalized exanthematous pustulosis with positive patch tests

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Terbinafine-induced lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Acute generalized exanthematous pustulosis induced by itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Erosion of psoriatic plaques: an early sign of methotrexate toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Fixed drug eruptions with feprazone are linked to HLA-B22

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Sweet's syndrome secondary to granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Sweet's syndrome induced by granulocyte colony-stimulating factor in a woman with congenital neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

In vivo and in vitro testing for adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Mechanisms of unpredictable adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Cutaneous pseudo-T-cell lymphomas. A clinicopathologic study of 20 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Mycosis fungoides—like lesions associated with phenytoin and carbamazepine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Blastomycosis-like pyoderma (Pyoderma vegetans) responding to antibiotics and topical disodium chromoglycate

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Lichenoid dermatitis after consumption of gold-containing liquor

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Clinical drug photosensitivity. A retrospective analysis of reports to the Norwegian Adverse Drug Reactions Committee from the years 1970-1994

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Paclitaxel and radiation-recall dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Histopathologic and immunohistochemical features in human skin after exposure to nitrogen and sulfur mustard

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Cross-reactivity in fixed drug eruptions to tetracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Interleukin-2 associated linear IgA bullous dermatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Porphyria cutanea tarda and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Pseudoporphyria caused by nabumetone

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Is mycosis fungoides exacerbated by fluoxetine?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

Hypersensitivity to paclitaxel manifested as a bullous fixed drug eruption

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970106-6

7 January 2021

10.1016/S0733-8635(05)70106-6

Identifiers

DOI

1 reference

28 July 2017

1 reference